{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:20:46Z","timestamp":1786656046955,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["SKGJ-MED-008"],"award-info":[{"award-number":["SKGJ-MED-008"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["223273\/F50"],"award-info":[{"award-number":["223273\/F50"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.schres.2017.10.042","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T09:01:22Z","timestamp":1510304482000},"page":"253-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis"],"prefix":"10.1016","volume":"197","author":[{"given":"Priyanthi B.","family":"Gjerde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Dieset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Z.","family":"Hoseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trude","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine V.","family":"Lagerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-1719","authenticated-orcid":false,"given":"Siv Hege","family":"Lyngstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragni H.","family":"M\u00f8rch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Melle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidar M.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/eip.12100","article-title":"Substance use in clinical high risk for psychosis: a review of the literature","volume":"8","author":"Addington","year":"2014","journal-title":"Early Interv. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.v60n0402","article-title":"The distribution of body mass index among individuals with and without schizophrenia","volume":"60","author":"Allison","year":"1999","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ajhg.2013.01.001","article-title":"Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors","volume":"92","author":"Andreassen","year":"2013","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.schres.2017.10.042_bb0025","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v64n0516","article-title":"Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics","volume":"64","author":"Atmaca","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2017.10.042_bb0030","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1176\/ajp.2006.163.7.1276","article-title":"Association of initial antipsychotic response to clozapine and long-term weight gain","volume":"163","author":"Bai","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.02.011","article-title":"Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia","volume":"93","author":"Bartzokis","year":"2007","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2012.06.036","article-title":"Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia","volume":"140","author":"Bartzokis","year":"2012","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.03.035","article-title":"Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy","volume":"161","author":"Bernstein","year":"2015","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/JCP.0b013e318166c4f7","article-title":"Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions","volume":"28","author":"Birkenaes","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2017.10.042_bb0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1176\/ajp.153.6.817","article-title":"Differential effect of clozapine on weight: a controlled study","volume":"153","author":"Bustillo","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.10.042_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.161","article-title":"A potential mechanism underlying atypical antipsychotics-induced lipid disturbances","volume":"5","author":"Cai","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0070","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.psychres.2013.08.056","article-title":"Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia","volume":"210","author":"Chen","year":"2013","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eurpsy.2013.04.003","article-title":"Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: severe negative syndrome may be related to a distinct lipid pathophysiology","volume":"29","author":"Chen","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2017.10.042_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.schres.2016.09.012","article-title":"Prevalence of metabolic syndrome in female and male patients at risk of psychosis","volume":"181","author":"Cordes","year":"2016","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2017.10.042_bb0085","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiat."},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0090","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: a differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.10.042_bb0095","first-page":"443","article-title":"White matter changes in schizophrenia","volume":"60","author":"Davis","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.schres.2017.10.042_bb0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-0179-2-14","article-title":"Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study","volume":"2","author":"De Hert","year":"2006","journal-title":"Clin. Pract. Epidemiol. Ment. Health"},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.schres.2017.10.042_bb0110","author":"Defined daily dose (DDD)"},{"issue":"8","key":"10.1016\/j.schres.2017.10.042_bb0115","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1503\/jpn.150030","article-title":"Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6weeks of selective dopamine D2\/3 receptor blockade","volume":"41","author":"Ebdrup","year":"2016","journal-title":"J. Psychiatry Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0125","first-page":"201","article-title":"Metabolic syndrome in drug-na\u00efve and drug-free patients with schizophrenia and in their siblings","volume":"166","author":"Enez Darcin","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.10.042_bb1000","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I\/P)","author":"First","year":"1996"},{"issue":"5","key":"10.1016\/j.schres.2017.10.042_bb0130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1017\/S1461145712001241","article-title":"Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial","volume":"16","author":"Fleischhacker","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2014.11.008","article-title":"Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms","volume":"25","author":"Goncalves","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","article-title":"Olanzapine: weight gain and therapeutic efficacy","volume":"19","author":"Gupta","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0145","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2011.01.022","article-title":"The association between weight change and symptom reduction in the CATIE schizophrenia trial","volume":"128","author":"Hermes","year":"2011","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.psychres.2012.02.019","article-title":"Impaired plasmalogens in patients with schizophrenia","volume":"198","author":"Kaddurah-Daouk","year":"2012","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4306\/pi.2015.12.2.242","article-title":"Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics","volume":"12","author":"Kang","year":"2015","journal-title":"Psychiatry Investig."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0165","first-page":"27","article-title":"Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol","volume":"130","author":"Krakowski","year":"2011"},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0269881112472568","article-title":"Increases in triglyceride levels are associated with clinical response to clozapine treatment","volume":"27","author":"Lally","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.10.042_bb0175","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/ajp.149.5.689","article-title":"Weight gain among schizophrenic patients treated with clozapine","volume":"149","author":"Lamberti","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0180","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4088\/JCP.v64n0314","article-title":"Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia","volume":"64","author":"Lane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1176\/ajp.149.1.68","article-title":"Clozapine-induced weight gain: prevalence and clinical relevance","volume":"149","author":"Leadbetter","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","article-title":"Clozapine-induced weight gain predicts improvement in psychopathology","volume":"59","author":"Meltzer","year":"2003","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.schres.2014.09.040","article-title":"Myelin, myelin-related disorders, and psychosis","volume":"161","author":"Mighdoll","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.10.042_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.psychres.2016.01.077","article-title":"Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism","volume":"238","author":"Misiak","year":"2016","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"Musil","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2015.04.031","article-title":"The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization","volume":"166","author":"Nasrallah","year":"2015","journal-title":"Schizophr. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2017.10.042_bb0220","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0225","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004850-200207000-00007","article-title":"Do triglycerides modulate the effectiveness of clozapine?","volume":"17","author":"Pande","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.10.042_bb0230","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J. Psychiatry Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0235","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4088\/JCP.v65n0415","article-title":"Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study","volume":"65","author":"Saari","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nn1426","article-title":"High cholesterol level is essential for myelin membrane growth","volume":"8","author":"Saher","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.schres.2017.10.042_bb0245","first-page":"791","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2014II","volume":"88","author":"Saunders","year":"1993"},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajp.2013.11.017","article-title":"Association between antipsychotic-induced metabolic side-effects and clinical improvement: a review on the Evidence for \u201cmetabolic threshold\u201d","volume":"8","author":"Sharma","year":"2014","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.schres.2017.10.042_bb0255","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psychres.2017.04.050","article-title":"Early clinical recovery in first-episode psychosis: symptomatic remission and its correlates at 1-year follow-up","volume":"254","author":"Simonsen","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2017.10.042_bb0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12888-016-1006-3","article-title":"Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study","volume":"16","author":"Solberg","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.10.042_bb0265","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.euroneuro.2016.07.011","article-title":"Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment","volume":"27","author":"Steen","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2017.10.042_bb0270","doi-asserted-by":"crossref","unstructured":"Tessier, C., Sweers, K., Frajerman, A., Bergaoui, H., Ferreri, F., Delva, C., Lapidus, N., Lamaziere, A., Roiser, J.P., De Hert, M., Nuss, P., 2016. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations. Transl. Psychiatry 6, e906.","DOI":"10.1038\/tp.2016.142"},{"key":"10.1016\/j.schres.2017.10.042_bb0275","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1192\/bjp.184.47.s76","article-title":"Metabolic disturbance in first-episode schizophrenia","volume":"47","author":"Thakore","year":"2004","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.schres.2017.10.042_bb0280","author":"Thematically Organized Psychosis (TOP) Study"},{"issue":"3","key":"10.1016\/j.schres.2017.10.042_bb0285","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/wps.20069","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls","volume":"12","author":"Vancampfort","year":"2013","journal-title":"World Psychiatry"},{"issue":"19","key":"10.1016\/j.schres.2017.10.042_bb0290","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1101\/gad.1116203","article-title":"Local regulation of fat metabolism in peripheral nerves","volume":"17","author":"Verheijen","year":"2003","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.schres.2017.10.042_bb0295","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4088\/JCP.08m04508","article-title":"Metabolic risk factors in drug-naive patients with first-episode psychosis","volume":"70","author":"Verma","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.10.042_bb0300","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.10.042_bb0305","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2013.07.051","article-title":"The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls","volume":"150","author":"Wu","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.10.042_bb0310","first-page":"8","article-title":"Behavioral and neurobiological changes in C57BL\/6 mouse exposed to cuprizone: effects of antipsychotics","volume":"4","author":"Xu","year":"2010","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.schres.2017.10.042_bb0315","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pnpbp.2014.08.015","article-title":"Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia","volume":"56","author":"Yang","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.10.042_bb0320","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"\u201cFirst do no harm\u201d. A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"Young","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.10.042_bb0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2016.09.001","article-title":"Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment","volume":"179","author":"Zhai","year":"2017","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417306709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417306709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T18:45:40Z","timestamp":1720205140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417306709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":66,"alternative-id":["S0920996417306709"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.10.042","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}